Wegovy is Novo Nordisk's brand of semaglutide for chronic weight management, cardiovascular risk reduction (March 2024) and MASH with F2 to F3 fibrosis (August 2025). It comes as a weekly pen and, since December 2025, a daily pill.
At a glance
- Generic name: semaglutide
- Manufacturer: Novo Nordisk
- List price: about $1,349 a month for pens (manufacturer list price, before insurance or discounts)
- Self-pay via NovoCare (read October 15, 2026): pens $349 a month at every dose from 0.25 to 2.4 mg; new patients pay $199 for each of their first two fills of 0.25 or 0.5 mg through December 31, 2026; Wegovy HD 7.2 mg $399; Wegovy pill $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg)
- Medicare: Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): a $50 copay for eligible Part D enrollees for Foundayo, Wegovy or the Zepbound KwikPen; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible and use their Part D plan instead.
FDA-approved indications
- Chronic weight management (2021)
- Pediatric obesity 12+ (2022)
- CV event reduction in adults with established CV disease and obesity or overweight — March 2024 (first weight-management drug approved to reduce CV risk; basis: SELECT trial)
- Noncirrhotic MASH with moderate to advanced fibrosis (F2 to F3) in adults — August 2025, accelerated approval (basis: ESSENCE part 1)
- Wegovy pill (oral semaglutide) for weight management and CV risk reduction — December 2025
Standard dosing
- Start: 0.25 mg/wk × 4 wk
- Titration: 0.5 → 1.0 → 1.7 → 2.4 mg, 4 wk at each step
- Maintenance: 2.4 mg weekly